Skip to main content

MW 519.3 Da, Purity >98%. Kinase inhibitor, commonly used as a protein kinase A inhibitor (IC50 = 135 nM). Also inhibits other kinases, including MSK1 , S6K1 and ROCKII (IC50 values are 120, 80 and 270 nM, respectively).

Be the first to review this product! Submit a review

Images

Chemical Structure - H89 dihydrochloride, Kinase inhibitor (AB120341), expandable thumbnail
  • Functional Studies - H89 dihydrochloride, Kinase inhibitor (AB120341), expandable thumbnail

Publications

Key facts

CAS number
130964-39-5
Purity
> 98%
Form
Solid
Molecular weight
519.3 Da
Molecular formula
C20H22BrCl2N3O2S
PubChem identifier
5702541
Nature
Synthetic

Alternative names

Recommended products

MW 519.3 Da, Purity >98%. Kinase inhibitor, commonly used as a protein kinase A inhibitor (IC50 = 135 nM). Also inhibits other kinases, including MSK1 , S6K1 and ROCKII (IC50 values are 120, 80 and 270 nM, respectively).

Key facts

Purity
> 98%
PubChem identifier
5702541
Biochemical name
H-89 Dihydrochloride
Biological description

Kinase inhibitor, commonly used as a protein kinase A inhibitor (IC50 = 135 nM). Also inhibits other kinases, including MSK1 , S6K1 and ROCKII (IC50 values are 120, 80 and 270 nM, respectively).

Canonical SMILES
C1=CC2=C(C=CN=C2)C(=C1)S(=O)(=O)NCCNCC=CC3=CC=C(C=C3)Br.Cl.Cl
Isomeric SMILES
C1=CC2=C(C=CN=C2)C(=C1)S(=O)(=O)NCCNC/C=C/C3=CC=C(C=C3)Br.Cl.Cl
InChI
InChI=1S/C20H20BrN3O2S.2ClH/c21-18-8-6-16(7-9-18)3-2-11-22-13-14-24-27(25,26)20-5-1-4-17-15-23-12-10-19(17)20;;/h1-10,12,15,22,24H,11,13-14H2;2*1H/b3-2+;;
InChIKey
GELOGQJVGPIKAM-WTVBWJGASA-N
IUPAC name
N-[2-[[(E)-3-(4-bromophenyl)prop-2-enyl]amino]ethyl]isoquinoline-5-sulfonamide;dihydrochloride

Storage

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions, The product can be stored for up to 12 months

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

AKT3 also known as Protein Kinase B gamma is a serine/threonine kinase that plays an important role in cell survival and metabolism. Along with AKT2 a closely related isoform AKT3 shares structural similarities but differs in tissue distribution and specific functions. AKT3 has a molecular weight of approximately 56 kDa. It is expressed in brain heart and testis tissues. Its catalytic activity is regulated by phosphorylation at two key residues contributing to its activation state.

Biological function summary

AKT3 and AKT2 influence processes like glucose uptake cell proliferation and suppression of apoptosis. These proteins do not form a stable complex but interact with other proteins as part of their activation and signaling processes. The cAMP Protein Kinase Catalytic subunit often called PKA C or PKAc is involved in similar pathways regulating numerous cellular processes through phosphorylation events. ROCK2 or Rho-associated coiled-coil containing protein kinase 2 acts in cytoskeletal dynamics influencing cell shape and movement.

Pathways

AKT3 participates in the PI3K/AKT signaling pathway important for transmitting extracellular signals into the cell influencing growth and survival. In this pathway AKT3 and AKT2 interact with proteins like mTOR and GSK-3 which help regulate cell cycle progression and metabolism. ROCK2 is mainly involved in the RhoA/ROCK pathway modulating actin cytoskeleton organization and affecting processes such as contraction cell migration and proliferation.

Associated diseases and disorders

AKT3 and AKT2 have been linked to cancer and insulin resistance. Mutations or aberrant activation can lead to excessive cell growth and survival contributing to tumorigenesis. Similarly dysregulation of AKT3 and AKT2 signaling can cause insulin resistance affecting glucose homeostasis. ROCK2 is connected to cardiovascular diseases influencing blood vessel tone and heart function. These proteins by being integral to these disease pathways present potential therapeutic targets and the use of kinase inhibitors like those targeting AKT and ROCK pathways can modulate their activity in disease contexts.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

  • Chemical Structure - H89 dihydrochloride, Kinase inhibitor (ab120341), expandable thumbnail

    Chemical Structure - H89 dihydrochloride, Kinase inhibitor (ab120341)

    2D chemical structure image of ab120341, H89 dihydrochloride, Kinase inhibitor

  • Functional Studies - H89 dihydrochloride, Kinase inhibitor (ab120341), expandable thumbnail
    Image from Tagashira, Hideki et al., PLOS One., 10(6):e0128678. Fig 8.; doi: 10.1371/journal.pone.0128678. Reproduced under the Creative Commons license http://creativecommons.org/licenses/by/4.0/

    Functional Studies - H89 dihydrochloride, Kinase inhibitor (ab120341)

    Normal human melanocytes (NHMs) were treated with ab120341 at the indicated concentrations to test if the inhibition of MSK1 activation results in the down-regulated MITF and EDNRB expression in UVB-exposed NHMs. ab120341 was added immediately after UVB irradiation and cells were cultured for 6h (for MITF, A) or 24 h (for EDNRB, B). Total mRNAs were purified and Real-time RT-PCR was carried out with MITF or EDNRB primer and β-actin primer as the internal control. Error bars represent S.D. from triplicate experiments. *P<0.05 and **P<0.01 against NHMs UVB-irradiated in the absence of H89, respectively.

    Tagashira, Hideki et al., PLOS One., 10(6):e0128678. Fig 8.; doi: 10.1371/journal.pone.0128678.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com